ArticleFrontiers in endocrinology2026
Reference intervals for intact FGF 23 in healthy Korean adults: lower concentrations in young adulthood require age-specific partitioning.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibroblast growth factor 23 (FGF23) is a bone-derived phosphaturic hormone that is essential for phosphate homeostasis. Elevated FGF23 levels underlie FGF23-related hypophosphatemic rickets and tumor-induced osteomalacia. Despite its clinical importance, population-based reference intervals (RIs) for intact FGF23 using the widely deployed LIAISON XL automated chemiluminescent immunoassay platform (DiaSorin) are lacking for East Asian populations. Methods: We established method-specific RIs for intact FGF23 (iFGF23) in 386 healthy Korean adults (193 males and 193 females; age, 20-79 years) following the Clinical and Laboratory Standards Institute EP28-A3c guidelines. After the Box-Cox transformation and Horn's outlier detection, the RIs were derived using nonparametric methods (2.5th-97.5th percentiles). The necessity for partitioning was assessed using the Harris-Boyd method. Associations between iFGF23 levels and demographic, anthropometric, and biochemical parameters were examined using Pearson's correlation coefficients. Results: The overall nonparametric RI was 28.04-100.33 pg/mL (90% CI: 25.77-31.91 to 96.29-109.20). Age emerged as the primary determinant requiring partitioning, with young adults (20-29 years) exhibiting significantly lower concentrations than older adults (≥30 years): 25.73-78.76 versus 32.01-107.00 pg/mL. A sex-stratified analysis confirmed that this age effect persisted independently in both males and females. Although males had higher median iFGF23 than females (65.03 vs. 51.98 pg/mL, Conclusions: This study provides the first population- and method-specific RIs for intact FGF23 in an East Asian population and establishes critical age-stratified benchmarks for clinical interpretation. The distinct RI in young adults underscores the necessity of age-appropriate reference standards for diagnosing and monitoring phosphate homeostasis disorders. These findings highlight the importance of population-specific reference data in the absence of assay harmonization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.